Table 1.
Baseline Characteristics of Pediatric Allogeneic Stem Cell Transplantation Patients at Risk for CMV
| Characteristics | Value |
|---|---|
| Overall | 91 |
| Age, median (range), yr | 7 (.3–23) |
| Sex | |
| Male | 44 (48) |
| Female | 47 (52) |
| Indication | |
| Leukemia | 42 (46) |
| MDS | 3 (3) |
| HLH | 6 (7) |
| Immunodeficiency | 17 (19) |
| Bone marrow failure | 11 (12) |
| Other | 12 (13) |
| Donor source | |
| Matched related | 36 (40) |
| Mismatched related | 1 (1) |
| Matched unrelated | 38 (42) |
| Mismatched unrelated | 7 (8) |
| UCB | 9 (10) |
| Reduced intensity conditioning | 9 (10) |
| GVHD prophylaxis calcineurin inhibitor | |
| Cyclosporine | 80 (88) |
| Tacrolimus | 11 (12) |
| Systemic corticosteroid use | |
| None | 41 (45) |
| Before day +50 | 45 (49) |
| After day +50 | 5 (5) |
| CMV serologic status (recipient/donor) | |
| Pos/pos | 28 (31) |
| Pos/neg | 36 (40) |
| Neg/pos | 26 (29) |
| Pos/ind | 1 (1) |
| CMV infection before SCT | |
| Yes | 6 (7) |
| No | 85 (93) |
MDS indicates myelodysplastic syndrome; HLH, hemophagocytic lymphohistiocytosis; pos, positive; neg, negative; ind, indeterminate.
Data presented are n (%), unless otherwise indicated.